http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Rodolfo V. Dizon (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Martin Kristoffer E. Ogbac ),( Rodolfo V. Dizon,Jr. ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Background: The Global Initiative for Asthma (GINA) 2019 guidelines recommend inhaled corticosteroids (ICS) with formoterol as the preferred reliever for asthma exacerbations. This results from several years of studies that identified the best reliever for asthma attacks. These included randomized controlled trials (RCTs), which followed strict protocols and parameters that may not be reflective of the actual practices by physicians and patients. Real-life studies are research trials that follow protocols but considers the techniques of physicians and adjustments by patients in an actual setting, thus being considered as having a more accurate outcome. We compared different real-life studies on the effects of ICS-formoterol and other reliever therapies for asthma exacerbations. Methods: Various published real-life studies comparing the effects of ICS-formoterol and other reliever therapies for asthma exacerbations were identified using PUBMED, MEDLINE, COCHRANE, and EMBASE. The studies were published from 208 to 2019. The primary outcome was the incidence of asthma exacerbations. Subset outcome analysis was performed comparing ICS-formoterol and short-acting beta agonists (SABA). Results: 3 real-life studies were included. Participants were 12 years and above. 2115 patients received ICS-formoterol. 1971 patients received other reliever therapies. ICS-formoterol group had severe exacerbation incidence of 7.57% and 10.35% for other relievers. Subset analysis revealed incidence of severe exacerbation of 7.62% for ICS-formoterol and 10.31% for SABA. There were less hospitalizations (5 vs 8) and emergency room (ER) consults (18 vs 22) with ICS-formoterol. Conclusions: Real-life studies are more reflective of the actual practices of physicians than RCTs. Its results are more accurate of the actual settings. In this meta-analysis of real-life studies, ICS-formoterol is statistically more favorable than other reliever therapies for asthma exacerbations. It is also more favorable than SABA as reliever therapy. There is no statistical difference between ICS-formoterol and other reliever therapies for steroid use after exacerbations.
-
( Martin Kristoffer E. Ogbac ),( Rodolfo V. Dizon,Jr. ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.0
A major consideration influencing the treatment for asthma exacerbation are side effects of the medications. The latest Global Initiative for Asthma (GINA) guidelines in the management of acute exacerbations of asthma recommends the use of inhaled corticosteroid (ICS) with formoterol. This has replaced the short-acting beta2 agonists (SABA) as the preferred reliever therapy. Majority of the adverse events with ICS-formoterol combination are upper respiratory tract infection (URTI) and headache while tremors and nausea were reported with SABA. We reviewed the safety and adverse events observed in recent trials comparing ICS-formoterol and SABA as reliever in asthma exacerbations. Recently published randomized controlled trials (RCT) comparing the effects of ICS-formoterol and SABA as for asthma exacerbations were found using PUBMED, MEDLINE, COCHRANE, and EMBASE. Included studies were published from 2006. Primary outcome was the incidence of total adverse events. Secondary outcome was is the most common side event for each therapy. 12 RCTs were included. Patients aging from 12 years old and above were selected. 8,703 patients received ICS-formoterol while 14,009 patients received SABA. The ICS-formoterol group had an adverse event incidence of 33.23 % while the SABA group had 32.55%. Based on the reported adverse events during these trials, the most common for both ICS-formoterol and SABA group was the development of respiratory tract infection. This is followed by nasopharyngitis. This analysis reviewed the different adverse events observed during the trials comparing the efficacy of ICS-formoterol and SABA for asthma exacerbations. This report did not statistically favor any reliever therapy in terms of incidence of adverse events as both groups have similar incidence of adverse events. Respiratory tract infection was also observed in both relievers as the major adverse event followed by nasopharyngitis. Safety profile of medications must also be considered in treating asthma exacerbations specially that new guidelines have released.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
